Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 4

1(14.3%)

Phase 1

1(14.3%)

N/A

1(14.3%)

7Total

Phase 2(4)

Phase 4(1)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02807649Not ApplicableCompleted

Effect of Ginko and Cistanche Against Fatigue Symptoms

Role: collaborator

NCT02284529Phase 4Completed

Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer

Role: lead

NCT01239511Phase 2Completed

Phase IIb Study of STA-2 in Patients With Chronic Stable Angina

Role: lead

NCT01255046Phase 2Unknown

Study of STA-1 as an Add-on Treatment to Donepezil

Role: lead

NCT01484912Phase 2Completed

Phase II Study of STA-2 in Patients With Chronic Stable Angina

Role: lead

NCT01475578Phase 2Completed

Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)

Role: lead

NCT00823186Phase 1Unknown

Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer

Role: collaborator

All 7 trials loaded